NasdaqGM:CSTLHealthcare
How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth
In January 2026, Castle Biosciences reported that 2025 total revenue is expected to exceed US$340 million, above its prior US$327–US$335 million range, alongside strong year-on-year growth in test volumes for its core DecisionDx-Melanoma and TissueCypher Barrett’s Esophagus assays.
The sharp increase in core test reports, particularly for TissueCypher, suggests that Castle’s efforts to broaden clinical adoption and utilization are gaining traction across its key diagnostic franchises.
Now...